FB   186.53 (-1.70%)
MSFT   154.63 (-2.24%)
GOOGL   1,277.40 (-2.86%)
AMZN   1,816.01 (-3.62%)
CGC   17.59 (-4.61%)
NVDA   248.21 (-1.74%)
MU   49.59 (-1.96%)
GE   10.10 (-2.79%)
TSLA   620.79 (-8.57%)
AMD   41.93 (-4.73%)
ACB   1.34 (-7.59%)
F   6.77 (-3.01%)
NFLX   366.82 (-1.32%)
PRI   109.48 (-4.62%)
GILD   69.31 (-4.61%)
DIS   113.89 (-3.52%)
FB   186.53 (-1.70%)
MSFT   154.63 (-2.24%)
GOOGL   1,277.40 (-2.86%)
AMZN   1,816.01 (-3.62%)
CGC   17.59 (-4.61%)
NVDA   248.21 (-1.74%)
MU   49.59 (-1.96%)
GE   10.10 (-2.79%)
TSLA   620.79 (-8.57%)
AMD   41.93 (-4.73%)
ACB   1.34 (-7.59%)
F   6.77 (-3.01%)
NFLX   366.82 (-1.32%)
PRI   109.48 (-4.62%)
GILD   69.31 (-4.61%)
DIS   113.89 (-3.52%)
FB   186.53 (-1.70%)
MSFT   154.63 (-2.24%)
GOOGL   1,277.40 (-2.86%)
AMZN   1,816.01 (-3.62%)
CGC   17.59 (-4.61%)
NVDA   248.21 (-1.74%)
MU   49.59 (-1.96%)
GE   10.10 (-2.79%)
TSLA   620.79 (-8.57%)
AMD   41.93 (-4.73%)
ACB   1.34 (-7.59%)
F   6.77 (-3.01%)
NFLX   366.82 (-1.32%)
PRI   109.48 (-4.62%)
GILD   69.31 (-4.61%)
DIS   113.89 (-3.52%)
FB   186.53 (-1.70%)
MSFT   154.63 (-2.24%)
GOOGL   1,277.40 (-2.86%)
AMZN   1,816.01 (-3.62%)
CGC   17.59 (-4.61%)
NVDA   248.21 (-1.74%)
MU   49.59 (-1.96%)
GE   10.10 (-2.79%)
TSLA   620.79 (-8.57%)
AMD   41.93 (-4.73%)
ACB   1.34 (-7.59%)
F   6.77 (-3.01%)
NFLX   366.82 (-1.32%)
PRI   109.48 (-4.62%)
GILD   69.31 (-4.61%)
DIS   113.89 (-3.52%)
Log in

NASDAQ:RIGL - Rigel Pharmaceuticals Stock Price, Forecast & News

$2.02
-0.02 (-0.98 %)
(As of 02/28/2020 10:04 AM ET)
Today's Range
$1.91
Now: $2.02
$2.12
50-Day Range
$2.04
MA: $2.39
$2.99
52-Week Range
$1.56
Now: $2.02
$3.10
Volume17,637 shs
Average Volume1.01 million shs
Market Capitalization$338.57 million
P/E RatioN/A
Dividend YieldN/A
Beta1.32
Rigel Pharmaceuticals, Inc, a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Phase III clinical study for autoimmune hemolytic anemia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:RIGL
CUSIP76655960
Phone650-624-1100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$44.51 million
Book Value$0.66 per share

Profitability

Net Income$-70,480,000.00

Miscellaneous

Employees158
Market Cap$338.57 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive RIGL News and Ratings via Email

Sign-up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.


Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) issued its quarterly earnings data on Thursday, February, 27th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.02. The biotechnology company earned $15.40 million during the quarter, compared to analyst estimates of $15.78 million. Rigel Pharmaceuticals had a negative net margin of 56.84% and a negative return on equity of 52.74%. During the same period in the previous year, the business posted $0.03 earnings per share. View Rigel Pharmaceuticals' Earnings History.

When is Rigel Pharmaceuticals' next earnings date?

Rigel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Rigel Pharmaceuticals.

What guidance has Rigel Pharmaceuticals issued on next quarter's earnings?

Rigel Pharmaceuticals updated its fourth quarter 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $15.4-15.4 million, compared to the consensus revenue estimate of $15.14 million.

What price target have analysts set for RIGL?

4 analysts have issued 1-year price targets for Rigel Pharmaceuticals' stock. Their forecasts range from $7.00 to $8.00. On average, they anticipate Rigel Pharmaceuticals' share price to reach $7.50 in the next year. This suggests a possible upside of 271.3% from the stock's current price. View Analyst Price Targets for Rigel Pharmaceuticals.

What is the consensus analysts' recommendation for Rigel Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rigel Pharmaceuticals.

Has Rigel Pharmaceuticals been receiving favorable news coverage?

Media headlines about RIGL stock have trended very negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Rigel Pharmaceuticals earned a news impact score of -3.5 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Rigel Pharmaceuticals.

Are investors shorting Rigel Pharmaceuticals?

Rigel Pharmaceuticals saw a increase in short interest during the month of February. As of February 14th, there was short interest totalling 15,300,000 shares, an increase of 42.6% from the January 30th total of 10,730,000 shares. Based on an average daily trading volume, of 1,570,000 shares, the days-to-cover ratio is currently 9.7 days. Currently, 9.3% of the shares of the stock are sold short. View Rigel Pharmaceuticals' Current Options Chain.

Who are some of Rigel Pharmaceuticals' key competitors?

What other stocks do shareholders of Rigel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include Rite Aid (RAD), Geron (GERN), Inovio Pharmaceuticals (INO), Terra Tech (TRTC), Catalyst Pharmaceuticals (CPRX), Fate Therapeutics (FATE), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Athersys (ATHX) and Progenics Pharmaceuticals (PGNX).

Who are Rigel Pharmaceuticals' key executives?

Rigel Pharmaceuticals' management team includes the folowing people:
  • Mr. Raul R. Rodriguez, Pres, CEO & Director (Age 58)
  • Ms. Dolly A. Vance, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 54)
  • Dr. Anne-Marie S. Duliege, Exec. VP & Chief Medical Officer (Age 60)
  • Mr. Eldon C. Mayer III, M.B.A., Exec. VP & Chief Commercial Officer (Age 58)
  • Dr. Thomas A. Raffin, Co-Founder (Age 72)

Who are Rigel Pharmaceuticals' major shareholders?

Rigel Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (13.63%), Tamarack Advisers LP (3.43%), State Street Corp (2.19%), Palo Alto Investors LP (2.11%), Goldman Sachs Group Inc. (1.86%) and Renaissance Technologies LLC (1.78%). Company insiders that own Rigel Pharmaceuticals stock include Anne-Marie Duliege, Dean L Schorno, Eldon C Mayer III, Nelson Cabatuan and Raul R Rodriguez. View Institutional Ownership Trends for Rigel Pharmaceuticals.

Which major investors are selling Rigel Pharmaceuticals stock?

RIGL stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., FMR LLC, Rhenman & Partners Asset Management AB, Granite Investment Partners LLC, Geode Capital Management LLC, Russell Investments Group Ltd., California Public Employees Retirement System and Palo Alto Investors LP. View Insider Buying and Selling for Rigel Pharmaceuticals.

Which major investors are buying Rigel Pharmaceuticals stock?

RIGL stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Jacobs Levy Equity Management Inc., Acadian Asset Management LLC, Panagora Asset Management Inc., Ikarian Capital LLC, Bank of Montreal Can, Tamarack Advisers LP and State Street Corp. Company insiders that have bought Rigel Pharmaceuticals stock in the last two years include Dean L Schorno, Eldon C Mayer III and Raul R Rodriguez. View Insider Buying and Selling for Rigel Pharmaceuticals.

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Rigel Pharmaceuticals' stock price today?

One share of RIGL stock can currently be purchased for approximately $2.02.

How big of a company is Rigel Pharmaceuticals?

Rigel Pharmaceuticals has a market capitalization of $338.57 million and generates $44.51 million in revenue each year. The biotechnology company earns $-70,480,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. Rigel Pharmaceuticals employs 158 workers across the globe.View Additional Information About Rigel Pharmaceuticals.

What is Rigel Pharmaceuticals' official website?

The official website for Rigel Pharmaceuticals is http://www.rigel.com/.

How can I contact Rigel Pharmaceuticals?

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-624-1100 or via email at [email protected]


MarketBeat Community Rating for Rigel Pharmaceuticals (NASDAQ RIGL)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  393 (Vote Outperform)
Underperform Votes:  315 (Vote Underperform)
Total Votes:  708
MarketBeat's community ratings are surveys of what our community members think about Rigel Pharmaceuticals and other stocks. Vote "Outperform" if you believe RIGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RIGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Featured Article: What is a back-end load?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel